Commerzbank Analysts Give Sartorius (SRT) a €101.00 Price Target

Commerzbank set a €101.00 ($117.44) price objective on Sartorius (ETR:SRT) in a research note issued to investors on Thursday. The brokerage currently has a sell rating on the stock.

Other analysts also recently issued research reports about the company. UBS Group set a €135.00 ($156.98) target price on Sartorius and gave the company a neutral rating in a research report on Wednesday, July 25th. Kepler Capital Markets set a €78.00 ($90.70) target price on Sartorius and gave the company a neutral rating in a research report on Tuesday, July 24th. Warburg Research set a €141.00 ($163.95) target price on Sartorius and gave the company a neutral rating in a research report on Tuesday, July 24th. Berenberg Bank set a €110.00 ($127.91) target price on Sartorius and gave the company a neutral rating in a research report on Tuesday, July 24th. Finally, Deutsche Bank set a €125.00 ($145.35) target price on Sartorius and gave the company a neutral rating in a research report on Friday, July 13th. Four analysts have rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. The company has an average rating of Hold and an average price target of €114.88 ($133.58).

ETR:SRT opened at €127.50 ($148.26) on Thursday.

About Sartorius

Sartorius Aktiengesellschaft provides pharmaceutical and laboratory equipment worldwide. The company operates through two divisions, Bioprocess Solutions, and Lab Products & Services. The Bioprocess Solutions division offers products, technologies, and services ranging from fermentation, cell cultivation, filtration, and purification to media storage and transportation for the biopharmaceutical industry.

Recommended Story: Book Value Per Share – BVPS

Analyst Recommendations for Sartorius (ETR:SRT)

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply